Drugs / Fluzone High-Dose Quadrivalent vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04551677 | Sep → Dec 2020 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-10-07 | Sanofi | Results Sanofi: Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations sanofi.com ↗
This is the first study to provide supportive evidence for vaccinating against influenza at the same time as a COVID-19 mRNA booster in seniors. |
All press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluzone High-Dose Quadrivalent vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04551677 ↗ |
| Known as | Fluzone High-Dose Quadrivalent | “Fluzone High-Dose Quadrivalent” NCT04551677 ↗ |
| Modality | Vaccine | “Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation” NCT04551677 ↗ |
| Route | Intramuscular | “Route of administration: IM” NCT04551677 ↗ |